1.Sales and profit
See section β- Rocket Pharmaceuticals, Inc. had $0.0M of revenue in fiscal 2025.
- Rocket Pharmaceuticals, Inc. lost $223M in fiscal 2025.
Rocket Pharmaceuticals, Inc.
RCKT Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Rocket Pharmaceuticals, Inc. had $0.0M of revenue in fiscal 2025.
- Today
- 7.5%
- Previous close
- $2.28
- Market cap
- $281M
- P/E
- β
- Day range
-
$2.25 $2.52
- 52-week range
-
$2.18 $5.30
Last close Β· Oct 27, 2026
$2.45
β$1.49 (β37.82%) past year
KIRAβs summary AI analyst
Hi! I read Rocket Pharmaceuticals, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
3 to watch
2.Cash and shareholders
See section β- Free cash flow was β$190M in fiscal 2025, β of revenue.
- In the last 12 months, insiders bought $0.0M and sold $0.9M of shares on the open market.
3.Financial health
See section β- Rocket Pharmaceuticals, Inc. passes 1 of 7 financial health tests (Piotroski F-score).
Rocket Pharmaceuticals, Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$223M
No. It lost money last year.
Weak
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$281M
Oct 27 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$0.17 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
KIRA summarises the numbers
-
Rocket Pharmaceuticals, Inc. had $0.0M of revenue in fiscal 2025.
Revenue
FY16
Revenue $0.0M
FY17
Revenue $0.0M
FY18
Revenue $0.0M
FY19
Revenue $0.0M
FY20
Revenue $0.0M
FY21
Revenue $0.0M
FY22
Revenue $0.0M
FY23
Revenue $0.0M
FY24
Revenue $0.0M
FY25
Revenue $0.0M
Revenue
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $0.0M
Q1 '24
Revenue $0.0M
Q2 '24
Revenue $0.0M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.0M
Q1 '26
Revenue $0.0M
Q2 '26
Revenue $0.0M
Margins, % of revenue
FY16
Gross β
Operating β
Net β
FCF β
FY17
Gross β
Operating β
Net β
FCF β
FY18
Gross β
Operating β
Net β
FCF β
FY19
Gross β
Operating β
Net β
FCF β
FY20
Gross β
Operating β
Net β
FCF β
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Rocket Pharmaceuticals, Inc. lost $223M in fiscal 2025.
Net income
FY16
Net income β$7.6M
FY17
Net income β$19.6M
FY18
Net income β$74.5M
FY19
Net income β$77.3M
FY20
Net income β$140M
FY21
Net income β$169M
FY22
Net income β$222M
FY23
Net income β$246M
FY24
Net income β$259M
FY25
Net income β$223M
Net income
Q3 '23
Net income β$61.9M
Q4 '23
Net income β$59.7M
Q1 '24
Net income β$62.1M
Q2 '24
Net income β$69.6M
Q3 '24
Net income β$66.7M
Q4 '24
Net income β$60.3M
Q1 '25
Net income β$61.3M
Q2 '25
Net income β$68.9M
Q3 '25
Net income β$50.3M
Q4 '25
Net income β$42.5M
Q1 '26
Net income β$47.6M
Q2 '26
Net income $123M
Diluted EPS
FY16
Diluted EPS β$1.11
FY17
Diluted EPS β$2.88
FY18
Diluted EPS β$1.89
FY19
Diluted EPS β$1.58
FY20
Diluted EPS β$2.52
FY21
Diluted EPS β$2.67
FY22
Diluted EPS β$3.26
FY23
Diluted EPS β$2.92
FY24
Diluted EPS β$2.73
FY25
Diluted EPS β$2.01
Diluted EPS
Q3 '23
Diluted EPS β$0.75
Q4 '23
Diluted EPS β$0.62
Q1 '24
Diluted EPS β$0.66
Q2 '24
Diluted EPS β$0.74
Q3 '24
Diluted EPS β$0.71
Q4 '24
Diluted EPS β$0.62
Q1 '25
Diluted EPS β$0.56
Q2 '25
Diluted EPS β$0.62
Q3 '25
Diluted EPS β$0.45
Q4 '25
Diluted EPS β$0.38
Q1 '26
Diluted EPS β$0.42
Q2 '26
Diluted EPS $1.08
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
KIRA summarises the numbers
-
Free cash flow was β$190M in fiscal 2025, β of revenue.
Free cash flow
FY16
Free cash flow β$5.8M
FY17
Free cash flow β$16.7M
FY18
Free cash flow β$55.2M
FY19
Free cash flow β$87.9M
FY20
Free cash flow β$95.2M
FY21
Free cash flow β$129M
FY22
Free cash flow β$187M
FY23
Free cash flow β$211M
FY24
Free cash flow β$216M
FY25
Free cash flow β$190M
Free cash flow
Q3 '23
Free cash flow β$61.8M
Q4 '23
Free cash flow β$34.0M
Q1 '24
Free cash flow β$58.9M
Q2 '24
Free cash flow β$55.8M
Q3 '24
Free cash flow β$53.7M
Q4 '24
Free cash flow β$47.3M
Q1 '25
Free cash flow β$56.2M
Q2 '25
Free cash flow β$49.0M
Q3 '25
Free cash flow β$50.4M
Q4 '25
Free cash flow β$34.9M
Q1 '26
Free cash flow β$45.5M
Q2 '26
Free cash flow β$39.6M
Cash from operations vs capital spending
FY16
Cash from operations β$5.5M
Capital spending $0.3M
FY17
Cash from operations β$16.0M
Capital spending $0.8M
FY18
Cash from operations β$53.8M
Capital spending $1.5M
FY19
Cash from operations β$64.7M
Capital spending $23.3M
FY20
Cash from operations β$74.6M
Capital spending $20.6M
FY21
Cash from operations β$121M
Capital spending $7.6M
FY22
Cash from operations β$178M
Capital spending $8.4M
FY23
Cash from operations β$195M
Capital spending $16.4M
FY24
Cash from operations β$210M
Capital spending $5.9M
FY25
Cash from operations β$190M
Capital spending $0.4M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$57.1M
Capital spending $4.7M
Q4 '23
Cash from operations β$29.3M
Capital spending $4.6M
Q1 '24
Cash from operations β$56.9M
Capital spending $2.0M
Q2 '24
Cash from operations β$53.8M
Capital spending $1.9M
Q3 '24
Cash from operations β$52.1M
Capital spending $1.6M
Q4 '24
Cash from operations β$46.9M
Capital spending $0.3M
Q1 '25
Cash from operations β$55.8M
Capital spending $0.4M
Q2 '25
Cash from operations β$49.0M
Capital spending $0.1M
Q3 '25
Cash from operations β$50.4M
Capital spending β$0.1M
Q4 '25
Cash from operations β$34.8M
Capital spending $0.1M
Q1 '26
Cash from operations β$45.4M
Capital spending $0.1M
Q2 '26
Cash from operations β$39.6M
Capital spending $0.0M
Cash from operations
Capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends, buybacks and share count
Dividends and buybacks
FY16
Dividends β
Buybacks $0.0M
FY17
Dividends β
Buybacks $0.0M
FY18
Dividends β
Buybacks $0.0M
FY19
Dividends β
Buybacks $0.0M
FY20
Dividends β
Buybacks $0.1M
FY21
Dividends β
Buybacks $0.0M
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY16
Diluted shares 0.01B
FY17
Diluted shares 0.01B
FY18
Diluted shares 0.04B
FY19
Diluted shares 0.05B
FY20
Diluted shares 0.06B
FY21
Diluted shares 0.06B
FY22
Diluted shares 0.07B
FY23
Diluted shares 0.08B
FY24
Diluted shares 0.09B
FY25
Diluted shares 0.11B
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders bought $0.0M and sold $0.9M of shares on the open market.
Bought, 12 months
$0.0M
1 insider
Sold, 12 months
$0.9M
6 insiders
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Martin WilsonGeneral Counsel | Sold | 75,364 | $3.40 | $0.3M | Form 4 |
| Aug 18, 2026 | Martin WilsonGeneral Counsel | Sold | 631 | $3.38 | $0.0M | Form 4 |
| Aug 18, 2026 | Gaurav ShahCEO | Sold | 2,293 | $3.38 | $0.0M | Form 4 |
| Aug 13, 2026 | Martin WilsonGeneral Counsel | Sold | 3,493 | $3.38 | $0.0M | Form 4 |
| Aug 13, 2026 | Gaurav ShahCEO | Sold | 2,837 | $3.38 | $0.0M | Form 4 |
| Aug 11, 2026 | Sarbani ChaudhuriSee Remarks | Sold | 4,701 | $3.50 | $0.0M | Form 4 |
| Aug 11, 2026 | Christopher James StevensChief Operating Officer | Sold | 36,658 | $3.50 | $0.1M | Form 4 |
| May 21, 2026 | Gaurav ShahCEO | Sold | 55,684 | $3.09 | $0.2M | Form 4 |
| May 19, 2026 | Gaurav ShahCEO | Sold | 2,409 | $3.01 | $0.0M | Form 4 |
| May 19, 2026 | Martin WilsonGeneral Counsel | Sold | 662 | $3.01 | $0.0M | Form 4 |
| May 19, 2026 | John MilitelloSee Remarks | Sold | 384 | $3.01 | $0.0M | Form 4 |
| May 13, 2026 | Gaurav ShahCEO | Sold | 2,728 | $3.61 | $0.0M | Form 4 |
| May 13, 2026 | Martin WilsonGeneral Counsel | Sold | 3,361 | $3.61 | $0.0M | Form 4 |
| May 13, 2026 | John MilitelloSee Remarks | Sold | 855 | $3.61 | $0.0M | Form 4 |
| May 7, 2026 | Sarbani ChaudhuriSee Remarks | Sold | 17,650 | $3.84 | $0.1M | Form 4 |
| Feb 18, 2026 | John MilitelloSee Remarks | Sold | 1,157 | $3.34 | $0.0M | Form 4 |
| Feb 18, 2026 | Martin WilsonGeneral Counsel | Sold | 1,376 | $3.34 | $0.0M | Form 4 |
| Feb 18, 2026 | Gaurav ShahCEO | Sold | 5,990 | $3.34 | $0.0M | Form 4 |
| Feb 13, 2026 | Martin WilsonGeneral Counsel | Sold | 12,253 | $3.31 | $0.0M | Form 4 |
| Feb 13, 2026 | John MilitelloSee Remarks | Sold | 3,726 | $3.31 | $0.0M | Form 4 |
| Feb 13, 2026 | Gaurav ShahCEO | Sold | 12,279 | $3.31 | $0.0M | Form 4 |
| Jan 2, 2026 | Elisabeth BjorkDirector | Bought | 10,000 | $3.44 | $0.0M | Form 4 |
| Nov 18, 2025 | Martin WilsonGeneral Counsel | Sold | 1,646 | $2.98 | $0.0M | Form 4 |
| Nov 18, 2025 | Jonathan David SchwartzSee Remarks | Sold | 2,545 | $2.98 | $0.0M | Form 4 |
| Nov 18, 2025 | John MilitelloSee Remarks | Sold | 1,086 | $2.98 | $0.0M | Form 4 |
| Nov 18, 2025 | Gaurav ShahCEO, Director | Sold | 6,276 | $2.98 | $0.0M | Form 4 |
| Oct 14, 2025 | John MilitelloSee Remarks | Sold | 28,918 | $3.96 | $0.1M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Rocket Pharmaceuticals, Inc. can carry it.
Cash vs debt (incl. leases)
FY16
Cash $126M
Debt β
FY17
Cash $18.1M
Debt β
FY18
Cash $206M
Debt β
FY19
Cash $304M
Debt β
FY20
Cash $483M
Debt β
FY21
Cash $389M
Debt β
FY22
Cash $356M
Debt β
FY23
Cash $373M
Debt β
FY24
Cash $372M
Debt β
FY25
Cash $189M
Debt β
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $389M | $356M | $373M | $372M | $189M |
| Interest coverage | β56.2x | β120.5x | β138.5x | β144.9x | β122.6x |
| Current ratio | 17.7x | 9.3x | 7.8x | 9.3x | 6.4x |
| Quick ratio | 17.7x | 9.3x | 7.8x | 9.3x | 6.4x |
| Total assets | $497M | $552M | $566M | $528M | $330M |
| Total liabilities | $42.3M | $62.1M | $73.8M | $64.5M | $53.2M |
| Shareholders' equity | $455M | $490M | $493M | $463M | $277M |
| Net debt (β = net cash) | β | β | β | β | β |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
FY16
Return on capital β
Return on equity β90.5%
Return on assets β5.8%
FY17
Return on capital β
Return on equity β163.9%
Return on assets β26.1%
FY18
Return on capital β
Return on equity β71.1%
Return on assets β54.9%
FY19
Return on capital β
Return on equity β30.8%
Return on assets β24.8%
FY20
Return on capital β
Return on equity β34.5%
Return on assets β29.0%
FY21
Return on capital β
Return on equity β35.3%
Return on assets β31.1%
FY22
Return on capital β
Return on equity β47.0%
Return on assets β42.3%
FY23
Return on capital β
Return on equity β50.0%
Return on assets β43.9%
FY24
Return on capital β
Return on equity β54.1%
Return on assets β47.3%
FY25
Return on capital β
Return on equity β60.3%
Return on assets β52.0%
Return on capital
Return on equity
Return on assets
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
KIRA summarises the numbers
-
Rocket Pharmaceuticals, Inc. passes 1 of 7 financial health tests (Piotroski F-score).
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 3 / 7 | 3 / 7 | 1 / 7 | 2 / 7 | 1 / 7 | 1 / 7 | 2 / 7 | 1 / 7 |
| Accruals ratio | β1.6% | β4.8% | β15.3% | β4.0% | β13.5% | β8.8% | β8.3% | β9.1% | β9.0% | β7.7% |
| Altman Z'' | β0.11 | β3.45 | 5.34 | 7.10 | 7.80 | 10.68 | 5.19 | 2.23 | 0.74 | β10.24 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Research and development | $6.0M | $14.9M | $53.3M | $57.9M | $105M | $125M | $166M | $186M | $171M | $142M |
| Operating income | β$7.6M | β$19.8M | β$71.2M | β$76.2M | β$134M | β$167M | β$224M | β$260M | β$273M | β$232M |
| Interest expense | $0.0M | $0.0M | $6.0M | $6.0M | $7.0M | $3.0M | $1.9M | $1.9M | $1.9M | $1.9M |
| Pretax income | β | β | β | β | β | β | β | β | β$259M | β$223M |
| Income tax | β | β | β | β | β | β | β | $0.0M | $0.0M | $0.0M |
| Net income | β$7.6M | β$19.6M | β$74.5M | β$77.3M | β$140M | β$169M | β$222M | β$246M | β$259M | β$223M |
| Net income to common | β$7.6M | β$19.6M | β$74.5M | β$77.3M | β$140M | β$169M | β$222M | β$246M | β$259M | β$223M |
| Diluted EPS | β$1.11 | β$2.88 | β$1.89 | β$1.58 | β$2.52 | β$2.67 | β$3.26 | β$2.92 | β$2.73 | β$2.01 |
| Diluted shares | 0.01B | 0.01B | 0.04B | 0.05B | 0.06B | 0.06B | 0.07B | 0.08B | 0.09B | 0.11B |
| Cash flow | ||||||||||
| Cash from operations | β$5.5M | β$16.0M | β$53.8M | β$64.7M | β$74.6M | β$121M | β$178M | β$195M | β$210M | β$190M |
| Capital expenditure | $0.3M | $0.8M | $1.5M | $23.3M | $20.6M | $7.6M | $8.4M | $16.4M | $5.9M | $0.4M |
| Free cash flow | β$5.8M | β$16.7M | β$55.2M | β$87.9M | β$95.2M | β$129M | β$187M | β$211M | β$216M | β$190M |
| Depreciation and amortization | $0.1M | $0.2M | $0.3M | $0.4M | $1.1M | $3.2M | $3.9M | $4.9M | $7.2M | $8.9M |
| Stock-based compensation | $0.3M | $1.3M | $13.6M | $13.4M | $18.6M | $29.2M | $31.0M | $39.4M | $43.9M | $37.1M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | β | β | β | β |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $126M | $18.1M | $206M | $304M | $483M | $389M | $356M | $373M | $372M | $189M |
| Finance lease liabilities | β | β | β | β | $20.6M | $20.8M | $21.0M | $21.1M | $21.2M | $21.3M |
| Current assets | $128M | $19.0M | $209M | $308M | $487M | $392M | $364M | $378M | $378M | $193M |
| Current liabilities | $7.0M | $4.5M | $15.4M | $18.3M | $32.6M | $22.2M | $39.2M | $48.5M | $40.7M | $30.2M |
| Property and equipment, net | $1.1M | $1.0M | $2.0M | $29.5M | $19.2M | $22.3M | $29.0M | $39.2M | $36.8M | $28.2M |
| Goodwill | β | $0.0M | $30.8M | $30.8M | $30.8M | $30.8M | $39.2M | $39.2M | $39.2M | $39.2M |
| Intangible assets | β | β | β | β | β | $0.0M | $25.7M | $25.2M | $25.2M | $25.2M |
| Total assets | $130M | $20.1M | $251M | $372M | $591M | $497M | $552M | $566M | $528M | $330M |
| Total liabilities | $56.5M | $4.6M | $57.3M | $64.8M | $87.3M | $42.3M | $62.1M | $73.8M | $64.5M | $53.2M |
| Shareholders' equity | $8.4M | $15.5M | $194M | $307M | $504M | $455M | $490M | $493M | $463M | $277M |
| Returns | ||||||||||
| Return on capital employed | β6.2% | β126.5% | β30.2% | β21.5% | β24.1% | β35.2% | β43.8% | β50.1% | β56.1% | β77.2% |
| Return on equity | β90.5% | β163.9% | β71.1% | β30.8% | β34.5% | β35.3% | β47.0% | β50.0% | β54.1% | β60.3% |
| Return on assets | β5.8% | β26.1% | β54.9% | β24.8% | β29.0% | β31.1% | β42.3% | β43.9% | β47.3% | β52.0% |
| Return on tangible equity | β90.5% | β126.2% | β45.7% | β27.9% | β29.6% | β39.9% | β52.2% | β57.3% | β64.9% | β104.8% |
| Growth | ||||||||||
| Share count change | β | β0.6% | 479.5% | 24.5% | 13.0% | 14.2% | 7.8% | 23.3% | 12.9% | 17.2% |
| Financial health | ||||||||||
| Interest coverage | β | β | β11.8x | β12.8x | β19.3x | β56.2x | β120.5x | β138.5x | β144.9x | β122.6x |
| Current ratio | 18.2x | 4.2x | 13.6x | 16.8x | 14.9x | 17.7x | 9.3x | 7.8x | 9.3x | 6.4x |
| Quick ratio | 18.2x | 4.2x | 13.6x | 16.8x | 14.9x | 17.7x | 9.3x | 7.8x | 9.3x | 6.4x |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 3.0 | 3.0 | 1.0 | 2.0 | 1.0 | 1.0 | 2.0 | 1.0 |
| Altman Z'' | β0.1 | β3.4 | 5.3 | 7.1 | 7.8 | 10.7 | 5.2 | 2.2 | 0.7 | β10.2 |
| Accruals ratio | β1.6% | β4.8% | β15.3% | β4.0% | β13.5% | β8.8% | β8.3% | β9.1% | β9.0% | β7.7% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001281895). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.